{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-22-000017","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2022-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.176311+00:00","generated_at":"2026-06-26T21:19:07.109402+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AnaptysBio CEO Hamza Suria resigns; Daniel Faga named Interim President and CEO","bullets":["Hamza Suria resigned as President, CEO and Class II director effective March 20, 2022.","Suria receives $603,580 salary continuation for 12 months and COBRA reimbursement; consulting through March 2023.","Daniel Faga, former Mirati COO and Spark CBO, appointed Interim CEO effective March 21, 2022.","Faga receives base salary $603,580, 55% target bonus, and 887,043 RSUs vesting over 24 months.","Faga's RSU vests fully on change of control termination or if new CEO hired; severance includes 12 months salary."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-22-000017","json":"https://secwatch.observer/filing/0001370053-22-000017.json","markdown":"https://secwatch.observer/filing/0001370053-22-000017.md","text":"https://secwatch.observer/filing/0001370053-22-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005322000017/0001370053-22-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005322000017/anab-20220320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:19:07.109402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad179c5d81","claim":"Daniel Faga was appointed as Interim President and Chief Executive Officer at ANAPTYSBIO, INC.","evidence_excerpt":"the Company appointed Daniel Faga, a Class I director of the Board, to serve as Interim President and Chief Executive Officer of the Company, effective as of March 21, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005322000017/0001370053-22-000017-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"eef36737f8","claim":"Hamza Suria resigned as President and Chief Executive Officer at ANAPTYSBIO, INC.","evidence_excerpt":"On March 20, 2022, Hamza Suria, provided notice to the board of directors (the “Board”) of AnaptysBio, Inc. (the “Company”) of his resignation as President and Chief Executive Officer and as a Class II director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005322000017/0001370053-22-000017-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}